Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
about
Advances in understanding prognosis in myeloma.Induction of site-specific chromosomal translocations in embryonic stem cells by CRISPR/Cas9.Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.Poor Outcomes in Hepatic Amyloidosis: A Report of 2 Cases.Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.Improving strategies for the diagnosis of cardiac amyloidosis.Attitudes about when and how to treat patients with AL amyloidosis: an international survey.Recent advances in the management of AL Amyloidosis.New and developing therapies for AL amyloidosis.Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.Outcomes of patients with renal monoclonal immunoglobulin deposition disease.Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement.Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.Importance of FISH genetics in light chain amyloidosis.New concepts in the treatment and diagnosis of amyloidosis.Factoring in the missing link.Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis.Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation.Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category.Light Chain Amyloidosis.Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival.Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.Novel Therapies in Light Chain Amyloidosis.Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.Recent advances in understanding and treating immunoglobulin light chain amyloidosis
P2860
Q30244061-DC4055F8-562F-4815-AF21-64279565A877Q36602551-028CD154-EEAE-4175-88AF-A8A1FAFD3130Q37094919-9FADA386-8ED8-4FC3-8F0F-AA7EBBA33BD5Q37330070-8806DD51-8163-47E0-B310-4303E4855C5FQ37570615-A19DB96C-956D-45B4-852A-AFDA8F8C6715Q38376616-CC9A4623-D266-4D6B-9C8E-7F1AA702CF64Q38547033-B340CAD3-2D17-4DC5-B782-A8B8471DAC60Q38600436-0ABA06CD-C1B4-4B8D-8D14-2CBDE813DA80Q38613822-CA31336E-BED3-489E-BA7A-1F07EB7D975AQ38779623-D2E650E7-25F1-4DA5-8451-A8EA90755EAFQ38928383-34215BE9-41D2-49C8-97C1-3432F93FDD42Q39217713-B67C9690-20ED-44FD-A027-54178117AA0CQ40274316-DCB4FB36-58C8-4F7F-945B-810835A26F37Q40362742-4E8A229B-CF63-4368-AEF0-9B56A5411F78Q40533557-55850C92-2E5D-45B9-A437-28A4449F474BQ40918755-F814C5AE-FC68-45CD-A189-C887E6667AA5Q41080053-767FD1CB-02ED-451E-BBD0-280196A0E0C7Q47135025-1958B846-6C6B-4D52-AD10-7F76DF863F07Q47561519-BE11C2DF-B646-4576-AB55-D75D57188A03Q48046525-C072CD99-C6F6-4AC2-B7A5-C9ED97A80B6BQ48139614-3F018625-2613-49E1-A7DE-7BA154A89E04Q48140288-ACFAFAF6-D6B6-4571-8B45-5B159FA8A082Q48187249-9044A648-5A0B-44BB-B51F-628DEE9D8549Q52659305-CB322D7C-8A30-4FA5-AC6C-58AD35B08303Q52777488-C93A1787-3FFB-46F0-9FB6-C20571871798Q55023498-DEB4FE35-4E39-4A86-AF28-AEC53362611BQ55127439-25221E1C-99EE-4619-A31B-F772FF8981F9Q55177621-1A75884E-02CA-4131-9436-CE0A12E3CFD8Q57166910-552D6DB6-7B51-4368-9838-DC64EFB9950B
P2860
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Translocation t(11;14) is asso ...... ith bortezomib-based regimens.
@en
type
label
Translocation t(11;14) is asso ...... ith bortezomib-based regimens.
@en
prefLabel
Translocation t(11;14) is asso ...... ith bortezomib-based regimens.
@en
P2093
P50
P356
P1476
Translocation t(11;14) is asso ...... ith bortezomib-based regimens.
@en
P2093
Anja Seckinger
Anna Jauch
Anthony D Ho
Axel Benner
Christina Kunz
Christoph Kimmich
Martin Granzow
Tilmann Bochtler
Ute Hegenbart
P304
P356
10.1200/JCO.2014.57.4947
P407
P577
2015-03-16T00:00:00Z